Fourth-Generation Fan Assessment Numeration System (FANS) Design and Performance Specifications

The Fan Assessment Numeration System (FANS) is a measurement device for generating ventilation fan performance curves. Three different-sized FANS currently exist for assessing ventilation fans commonly used in poultry and livestock housing systems. All FANS consist of an array of anemometers inside an aluminum shroud that traverse the inlet or outlet of a ventilation fan. The FANS design has been updated several times since its inception and is currently in its fourth-generation (G4). The current design iteration (FANS-G4) is reported in this article with an emphasis on the hardware and software control, data acquisition systems, and operational reliability. Six FANS-G4 units were fabricated at the University of Kentucky (UK) Agricultural Machinery Research Laboratory and calibrated at the University of Illinois Urbana-Champaign (UIUC) Bioenvironmental and Structural Systems (BESS) Laboratory. Results demonstrated that the FANS-G4 was capable of measuring volumetric airflow to within 0.6% of full-scale (FS), which ranged from 15,000 to 56,000 m3 h-1

Impact of fiber source and feed particle size on swine manure properties related to spontaneous foam formation during anaerobic decomposition

Foam accumulation in deep-pit manure storage facilities is of concern for swine producers because of the logistical and safety-related problems it creates. A feeding trial was performed to evaluate the impact of feed grind size, fiber source, and manure inoculation on foaming characteristics. Animals were fed: (1) C–SBM (corn–soybean meal): (2) C–DDGS (corn–dried distiller grains with solubles); and (3) C–Soybean Hull (corn–soybean meal with soybean hulls) with each diet ground to either fine (374 μm) or coarse (631 μm) particle size. Two sets of 24 pigs were fed and their manure collected. Factors that decreased feed digestibility (larger grind size and increased fiber content) resulted in increased solids loading to the manure, greater foaming characteristics, more particles in the critical particle size range (2–25 μm), and a greater biological activity/potential

Effect of Bonny Light Crude Oil Pollution of Soil on the Growth of dayflower (Commelina benghalensis L.) in the Niger Delta, Nigeria

The effect of Bonny Light Crude oil pollution of soil and successive plantings in the same soil at 4 - week intervals on the growth of dayflower ( Commelina benghalensis L. ) was investigated. The factorial sets of treatments were two levels of oil pollution (0 and 50 mg/g) and 5 successive plantings. Characters assessed were mean plant height, leaf area per plant and mean dry matter weight. At each of the 5 croppings mean plant characters assessed were significantly higher (P = 0.05) at 0 mg/g oil pollution than at the 50 mg oil/g soil pollution level. In the control treatments, a declining trend in plant growth was observed from the 1st to the 5th crop. In contrast, in the oil-treated soils, an increasing trend was observed. @JASE

Differential hippocampal shapes in posterior cortical atrophy patients: A comparison with control and typical AD subjects.

Posterior cortical atrophy (PCA) is a neurodegenerative syndrome characterized by predominant visual deficits and parieto-occipital atrophy, and is typically associated with Alzheimer's disease (AD) pathology. In AD, assessment of hippocampal atrophy is widely used in diagnosis, research, and clinical trials; its utility in PCA remains unclear. Given the posterior emphasis of PCA, we hypothesized that hippocampal shape measures may give additional group differentiation information compared with whole-hippocampal volume assessments. We investigated hippocampal volume and shape in subjects with PCA (n = 47), typical AD (n = 29), and controls (n = 48). Hippocampi were outlined on MRI scans and their 3D meshes were generated. We compared hippocampal volume and shape between disease groups. Mean adjusted hippocampal volumes were ∼8% smaller in PCA subjects (P < 0.001) and ∼22% smaller in tAD subject (P < 0.001) compared with controls. Significant inward deformations in the superior hippocampal tail were observed in PCA compared with controls even after adjustment for hippocampal volume. Inward deformations in large areas of the hippocampus were seen in tAD subjects compared with controls and PCA subjects, but only localized shape differences remained after adjusting for hippocampal volume. The shape differences observed, even allowing for volume differences, suggest that PCA and tAD are each associated with different patterns of hippocampal tissue loss that may contribute to the differential range and extent of episodic memory dysfunction in the two groups. Hum Brain Mapp, 2015. © 2015 The Authors Human Brain Mapping Published by Wiley Periodicals, Inc

Predicting Sustained Clinical Response to Rituximab in Moderate to Severe Systemic Manifestations of Primary Sjögren Syndrome

Objective To assess outcomes of repeat rituximab cycles and identify predictors of sustained clinical response in systemic manifestations of primary Sjögren syndrome (pSS). Methods An observational study was conducted in 40 rituximab-treated patients with pSS. Clinical response was defined as a 3-point or more reduction in the European League Against Rheumatism (EULAR) Sjögren Disease Activity Index (ESSDAI) at 6 months from baseline. Peripheral blood B cells were measured using highly sensitive flow cytometry. Predictors of sustained response (within two rituximab cycles) were analyzed using penalized logistic regression. Results Thirty-eight out of 40 patients had moderate to severe systemic disease (ESSDAI >5). Main domains were articular (73%), mucocutaneous (23%), hematological (20%), and nervous system (18%). Twenty-eight out of 40 (70%) patients were on concomitant immunosuppressants. One hundred sixty-nine rituximab cycles were administered with a total follow-up of 165 patient-years. In cycle 1 (C1), 29/40 (73%) achieved ESSDAI response. Of C1 responders, 23/29 received retreatment on clinical relapse, and 15/23 (65%) responded. Of the 8/23 patients who lost response, these were due to secondary non-depletion and non-response (2NDNR; 4/23 [17%] as we previously observed in systemic lupus erythematosus with antirituximab antibodies, inefficacy = 2/23, and other side effects = 2/23). Within two cycles, 13/40 (33%) discontinued therapy. In multivariable analysis, concomitant immunosuppressant (odds ratio 7.16 [95% confidence interval: 1.37–37.35]) and achieving complete B-cell depletion (9.78 [1.32–72.25]) in C1 increased odds of response to rituximab. At 5 years, 57% of patients continued on rituximab. Conclusion Our data suggest that patients with pSS should be co-prescribed immunosuppressant with rituximab, and treatment should aim to achieve complete depletion. About one in six patients develop 2NDNR in repeat cycles. Humanized or type 2 anti-CD20 antibodies may improve clinical response in extra-glandular pSS

The WOMAN trial: clinical and contextual factors surrounding the deaths of 483 women following post-partum haemorrhage in developing countries.

BACKGROUND: Post-partum haemorrhage (PPH) is a leading cause of maternal death worldwide. The WOMAN trial assessed the effects of tranexamic acid (TXA) on death and surgical morbidity in women with PPH. The trial recorded 483 maternal deaths. We report the circumstances of the women who died. METHODS: The WOMAN trial recruited 20,060 women with a clinical diagnosis of PPH after a vaginal birth or caesarean section. We randomly allocated women to receive TXA or placebo. When a woman died, we asked participating clinicians to report the cause of death and to provide a short narrative of the events surrounding the death. We collated and edited for clarity the narrative data. RESULTS: Case fatality rates were 3.0% in Africa and 1.7% in Asia. Nearly three quarters of deaths were within 3 h of delivery and 91% of these deaths were from bleeding. Women who delivered outside a participating hospital (12%) were three times more likely to die (OR = 3.12, 95%CI 2.55-3.81) than those who delivered in hospital. Blood was often unavailable due to shortages or because relatives could not afford to buy it. Clinicians highlighted late presentation, maternal anaemia and poor infrastructure as key contributory factors. CONCLUSIONS: Although TXA use reduces bleeding deaths by almost one third, mortality rates similar to those in high income countries will not be achieved without tackling late presentation, maternal anaemia, availability of blood for transfusion and poor infrastructure